FDA Advisory Committee Votes to Recommend Six Peptides for Compounding Pharmacy Use

Published Jul 27, 08:45 PM UTC

The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to the 503A bulks list, potentially allowing compounding pharmacies to produce customized medications. The vote follows growing demand for unapproved peptides promoted by wellness influencers, with U.S. imports from China doubling to $328 million in 2025. HHS Secretary Robert F. Kennedy Jr. has advocated for legal access, arguing the current ban creates a dangerous black market. The committee rejected emideltide for opioid withdrawal and insomnia. FDA scientists had recommended against the additions due to insufficient safety evidence. The FDA typically follows committee advice but final regulations could take months or years.